Daily Research News Online

The global MR industry's daily paper since 2000

IMS Health Reports 6.1% Second Quarter Revenue Rise

July 25 2014

Pharma research giant IMS Health has reported a 6.1% increase in second quarter revenue to $662m. However, due to a number of one-off charges and expenses the firm suffered a Q2 net loss of $200m, compared with net income of $8m in the prior year period.

Ari BousbibAdjusted EBITDA increased 9.2% to $226m. The net loss figure was driven by charges relating to the firm's IPO, and $27m of restructuring and related charges. Adjusted net income was up 39.8% to $134m, due to the $20m increase in Adjusted EBITDA and a $25m reduction in interest expense.

Chairman and CEO Ari Bousbib (pictured) says of the results: 'We delivered another strong quarter of revenue and Adjusted EBITDA growth through steady execution of our strategy. Our recent successful IPO and debt refinancing position us well to significantly increase earnings and cash flow and, at the same time, to continue investing for future growth, including the pending transaction with Cegedim.'

Revenue for the six months ended June 30th increased 5.7% to $1,307m, while Adjusted EBITDA increased 8.2% to $443m. First half net loss was $244m, compared with net income of $20m in H1 2013, but adjusted net income was up 18.5% to $204m.

Web site: www.imshealth.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

Select a region below...
View all recent news
for UK
UK
USA
View all recent news
for USA
View all recent news
for Asia
Asia
Australia
View all recent news
for Australia

REGISTER FOR NEWS EMAILS

To receive (free) news headlines by email, please register online